Neurocrine gets U.S. nod for Parkinson's therapy; COVID-19 delays launch [Reuters]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Reuters
Neurocrine gets U.S. nod for Parkinson's therapy; COVID-19 delays launch (Reuters) - Neurocrine Biosciences Inc said on Monday its add-on treatment for patients with Parkinson’s disease received U.S. approval, but the launch will be delayed until later this year because of disruptions caused by the COVID-19 pandemic. As the virus outbreak prompts social distancing and forces hospitals to cancel unnecessary visits, including from drug sales personnel, operations of pharmaceutical companies are getting disrupted, including launches. “This is not an appropriate time to launch the drug into the neurology community,” Neurocrine Chief Executive Officer Kevin Gorman told Reuters ahead of the announcement of the drug’s approval by the U.S. Food and Drug Administration. A month’s supply of the drug, Ongentys, would have a list price below $670 - around the range of other similar drugs in the market, Gorman said, adding it was working with its partner, Portugal-based BIAL Portela & Ca SA to sup
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at TD Cowen from $175.00 to $200.00. They now have a "buy" rating on the stock.MarketBeat
- Neurocrine Biosciences (NBIX): Revisiting Valuation Following Decade-Long VMAT2 Review Publication [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) CapsulesPR Newswire
- Neurona Therapeutics Appoints Dr. Eduardo Dunayevich as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Assessing Neurocrine Biosciences After Stock Rises 7.8% and Partnership Expansion News [Yahoo! Finance]Yahoo! Finance
NBIX
Earnings
- 10/28/25 - Beat
NBIX
Sec Filings
- 12/4/25 - Form 4
- 12/3/25 - Form 144
- 12/2/25 - Form 4
- NBIX's page on the SEC website